Skip to main content
XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
1.800
0.00 (0.00%)
Apr 29, 2026, 1:51 PM IDT

XTL Biopharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
 Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Net Income
--1.03-1.78-1.350.44-2.95
Upgrade
Depreciation & Amortization
-0.2-000
Upgrade
Loss (Gain) From Sale of Investments
--0.171.021.53-0.75-0.14
Upgrade
Stock-Based Compensation
-0.2600.010.040.05
Upgrade
Other Operating Activities
--1.08-0.01-1.08-0.722.15
Upgrade
Change in Accounts Receivable
-0.04----
Upgrade
Change in Accounts Payable
-0.210.02-0.04-0.020.02
Upgrade
Change in Other Net Operating Assets
--0.060.050.03-0.030.02
Upgrade
Operating Cash Flow
--1.62-0.71-0.9-1.05-0.85
Upgrade
Capital Expenditures
--0.05----0
Upgrade
Cash Acquisitions
--0.41----
Upgrade
Investment in Securities
--0.01----
Upgrade
Other Investing Activities
-0.030.040.040.010.03
Upgrade
Investing Cash Flow
--0.840.040.040.010.03
Upgrade
Long-Term Debt Repaid
--0.01----
Upgrade
Net Debt Issued (Repaid)
--0.01----
Upgrade
Issuance of Common Stock
-1.46--0.39-
Upgrade
Financing Cash Flow
-1.45--0.39-
Upgrade
Foreign Exchange Rate Adjustments
--0.02-0.03-0.01-0.01-0.01
Upgrade
Net Cash Flow
--1.03-0.69-0.88-0.66-0.82
Upgrade
Free Cash Flow
--1.67-0.71-0.9-1.05-0.85
Upgrade
Free Cash Flow Margin
--370.73%----
Upgrade
Free Cash Flow Per Share
--0.00-0.00-0.00-0.00-0.00
Upgrade
Levered Free Cash Flow
-0.74-0.41-0.55-0.66-0.5
Upgrade
Unlevered Free Cash Flow
-0.76-0.41-0.55-0.66-0.5
Upgrade
Change in Working Capital
-0.190.06-0.02-0.050.05
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.